No Data
No Data
What to Expect From TransMedics Gr's Earnings
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
Promising Outlook and Attractive Entry Point: Josh Jennings' Buy Rating on TransMedics Group
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Collegium Pharmaceutical (COLL) and Korro Bio (KRRO)
Earnings Preview: TransMedics to Report Financial Results Post-market on October 28
$TransMedics(TMDX.US)$ is scheduled to release its financial results post-market on October 28 ET. Earnings PreviewAnalysts estimate $TransMedics(TMDX.US)$ to post revenue of USD115.00M for 2024Q3,
With A 25% Price Drop For TransMedics Group, Inc. (NASDAQ:TMDX) You'll Still Get What You Pay For